Qualitative antimicrobial susceptibility testing (AST) for Proteus species determines whether clinical, food, or environmental isolates are categorized as Susceptible (S), Intermediate (I), or Resistant (R) to therapeutically relevant antibiotics. Performed primarily by the standardized Kirby–Bauer disk diffusion method in accordance with CLSI, EUCAST, and ISO 20776-2 standards, this testing provides rapid, actionable guidance for infection treatment and antimicrobial resistance surveillance. This article outlines the sample types, tested antimicrobial panels, methodology, quality control requirements, and typical applications of qualitative Proteus AST services offered by accredited third-party laboratories.
Technical Overview
Proteus is a genus of motile, Gram-negative, facultatively anaerobic bacilli belonging to the order Enterobacterales. The most clinically significant species include Proteus mirabilis, Proteus vulgaris, Proteus penneri, and Proteus hauseri. Characterized by their distinctive swarming growth on agar media and urease production, these organisms are a frequent cause of urinary tract infections, wound and burn infections, catheter-associated infections, and occasionally bacteremia and opportunistic nosocomial infections.
Qualitative antimicrobial susceptibility testing categorizes a Proteus isolate into one of three interpretive categories — Susceptible (S), Intermediate (I), or Resistant (R) — based on inhibition zone diameters produced in the disk diffusion assay. This contrasts with quantitative methods (such as broth microdilution or agar dilution MIC determination) that report a minimum inhibitory concentration value. The qualitative approach is widely favored for routine workflows because it is simple, low-cost, reproducible, and rapid, typically delivering results within 24 hours of isolate preparation.
Testing is performed in accordance with internationally recognized standards, including CLSI documents M02 (Performance Standards for Antimicrobial Disk Susceptibility Tests) and M100 (Performance Standards for Antimicrobial Susceptibility Testing), the EUCAST disk diffusion method, and ISO 20776-2 (Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 2: Evaluation of performance of antimicrobial susceptibility test devices).
An important microbiological consideration is that Proteus species exhibit predictable intrinsic resistance to certain agents, including colistin (polymyxin E), polymyxin B, nitrofurantoin, and tetracyclines. These agents are excluded from test panels and reports for Proteus, as testing them would yield misleading results.
Testing Samples
Clinical Isolates
Accepted clinical materials include pure cultures recovered from urine specimens (the most common source, given the strong association of P. mirabilis with catheter-associated and complicated urinary tract infections), wound exudates and pus, lower respiratory tract secretions, positive blood culture bottles, catheter tips, and tissue biopsies. Primary specimens are first subcultured onto non-selective media to confirm purity and obtain fresh, 18–24 hour growth for inoculum preparation.
Food and Feed Samples
Proteus species serve as hygiene and spoilage indicator organisms in food microbiology. Isolates recovered from raw meat and poultry, seafood, dairy products, eggs, ready-to-eat foods, and animal feed during routine enumeration or identification testing can be submitted for resistance profiling as part of food safety monitoring programs.
Environmental and Water Samples
Isolates obtained from hospital environmental surfaces, pharmaceutical-grade water systems, cosmetics and personal care products, and general environmental monitoring swabs may be tested to assess the resistance reservoir and support contamination investigations.
Submission Requirements
- Fresh, pure culture on agar slant or plate (18–24 hour growth recommended; older subcultures may affect viability and expression of resistance mechanisms)
- Confirmed identification to genus or species level (MALDI-TOF MS, biochemical systems, or molecular methods), as interpretive breakpoints are organism-group specific
- Clearly labeled specimen source, collection date, and requested antimicrobial panel or formulary
- Proper transport conditions (2–8 °C for short transit; ambient for actively growing slants) in compliance with biological substance shipping regulations
Testing Items
Qualitative AST panels for Proteus are structured around Enterobacterales breakpoints. Commonly tested antimicrobial agents include:
- Beta-lactam penicillins: ampicillin, amoxicillin, piperacillin, amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam
- Cephalosporins: cefazolin, cefuroxime, cefotaxime, ceftriaxone, ceftazidime, cefepime, cefoperazone-sulbactam, ceftazidime-avibactam
- Monobactam: aztreonam
- Carbapenems: imipenem, meropenem, ertapenem
- Fluoroquinolones: ciprofloxacin, levofloxacin
- Aminoglycosides: gentamicin, tobramycin, amikacin
- Folate pathway inhibitors: trimethoprim-sulfamethoxazole
- Phenicols: chloramphenicol (where clinically or epidemiologically relevant)
Agents intrinsically inactive against Proteus — colistin, polymyxin B, nitrofurantoin, and tetracyclines — are not tested or reported. When clinical or epidemiological indication exists, supplementary phenotypic screening and confirmatory tests for extended-spectrum beta-lactamase (ESBL) production, typically involving cefotaxime and ceftazidime disks alone and in combination with clavulanic acid, are performed alongside the routine panel.
Testing Methods
Kirby–Bauer Disk Diffusion (Primary Qualitative Method)
The standardized disk diffusion procedure is executed as follows:
- Preparation of a bacterial suspension equivalent to a 0.5 McFarland turbidity standard from fresh, pure colonies
- Inoculation onto Mueller–Hinton agar plates within 15 minutes of suspension preparation to ensure uniform, confluent growth
- Application of antimicrobial-impregnated paper disks onto the inoculated surface within 15 minutes, with disks placed no closer than 24 mm apart to prevent overlapping inhibition zones
- Incubation at 35 ± 2 °C in ambient air for 16–24 hours
- Measurement of inhibition zone diameters to the nearest millimeter using a calibrated ruler or automated zone reader, with transmitted light used to visualize subtle growth
- Interpretation of zone diameters against current CLSI M100 or EUCAST breakpoint tables, assigning S, I, or R categories
ESBL Phenotypic Confirmation (Double-Disk Synergy)
For isolates demonstrating reduced susceptibility to indicator cephalosporins, confirmatory ESBL testing is performed by comparing zone diameters of cefotaxime and ceftazidime disks with their clavulanate-containing counterparts. A enhancement of the inhibition zone in the presence of clavulanic acid confirms ESBL production, which mandates reporting of all penicillins, cephalosporins, and aztreonam as resistant regardless of in vitro results, per standard reporting rules.
Quality Control and Assurance
- Reference strains such as Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 are tested in parallel with each batch to verify disk potency, medium performance, and inoculum density, with zone diameters required to fall within published acceptable ranges
- Media pH (7.2–7.4), thickness (approximately 4 mm), and cation content are controlled per CLSI M02 and ISO 20776-2 requirements
- Disk storage conditions (–20 °C to 8 °C with desiccant) and working stock handling are documented to guarantee antimicrobial stability
- Technologists are trained and competency-assessed; results undergo dual review, and unusual resistance patterns (such as carbapenem resistance in Proteus) trigger repeat testing and molecular or phenotypic confirmatory workup
All procedures are performed within an ISO/IEC 17025-aligned quality management system at accredited third-party laboratories, ensuring traceability, reproducibility, and defensible reporting.
Applications
- Clinical therapy guidance: directing empirical-to-targeted antimicrobial selection for urinary tract infections, wound infections, osteomyelitis, and bacteremia caused by Proteus species, supporting antimicrobial stewardship programs
- Infection control and surveillance: identification of multidrug-resistant (MDR), ESBL-producing, or carbapenem-resistant isolates within healthcare facilities to trigger isolation precautions and outbreak investigations
- Public health monitoring: contribution of Proteus resistance data to national and international antimicrobial resistance surveillance networks, including foodborne and community-associated resistance trend analysis
- Food safety and hygiene assessment: evaluation of resistance burdens in Proteus isolates recovered from food production chains, slaughterhouses, and retail products, informing sanitation and process control decisions
- Pharmaceutical and water quality: characterization of isolates from purified water systems, non-sterile products, and environmental monitoring programs in GMP-regulated facilities
- Research support: supplying categorical resistance profiles for epidemiological studies, resistance mechanism investigations, and new antimicrobial agent evaluation
FAQ
What is the difference between qualitative and quantitative AST?
Qualitative AST reports a categorical result — Susceptible, Intermediate, or Resistant — derived from inhibition zone diameters in disk diffusion. Quantitative AST reports a numerical minimum inhibitory concentration (MIC), usually in µg/mL, obtained by broth microdilution or agar dilution. Both approaches apply the same underlying breakpoints, and qualitative testing is preferred for routine screening due to its speed and simplicity.
Why are colistin, nitrofurantoin, and tetracyclines not reported for Proteus?
Proteus species possess intrinsic resistance mechanisms to these agents — including a naturally occurring chromosomal gene conferring polymyxin resistance and impermeability-related traits — so in vitro susceptibility testing would not predict clinical efficacy. Current CLSI and EUCAST guidance excludes these agents from Proteus test menus and reports.
How long does testing take?
Once a pure, confirmed isolate is received, disk diffusion results are typically available within 24–48 hours, including incubation, zone reading, interpretation, and report review. ESBL confirmatory testing may add one additional working day.
Which standards govern the procedure?
The principal references are CLSI M02 and CLSI M100 (disk diffusion methodology and breakpoint tables for Enterobacterales), the EUCAST disk diffusion method and breakpoint guidance, and ISO 20776-2 for the evaluation and performance of susceptibility test devices. Reports cite the breakpoint version applied to ensure longitudinal comparability.
Can the test detect ESBL or carbapenemase production?
The routine qualitative panel includes screening markers for ESBL production, and confirmatory double-disk synergy testing is available on request. Suspected carbapenem resistance is flagged and can be escalated to molecular detection of resistance genes such as blaKPC, blaNDM, or blaOXA-48-type determinants as a supplementary service.
What specimen sources are most commonly submitted?
Urine-derived isolates predominate, reflecting the strong association of Proteus mirabilis with urinary tract infections, followed by wound and soft tissue isolates, blood culture isolates, and food or environmental strains submitted for hygiene and surveillance purposes.
